FDA Approves New Nuplazid Formulation, Dosage Strength

By June 29, 2018

Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson's disease psychosis.

Parkinson's Medications Tied to Impulse Control Disorders

June 21, 2018

The 5-year cumulative incidence of ICDs was 46.1% in 306 patients without ICDs at baseline (DA ever-users, 51.5%; DA never users, 12.4%).

Incidence of Extrapyramidal Symptoms Higher With Certain Antidepressants

By June 18, 2018

Within the cohort, 3838 cases were identified and compared with 38,380 age-matched controls.

FDA to Review Sublingual Tx for Motor Fluctuations in Parkinson's Disease

By June 13, 2018

The film is a new formulation of the dopamine agonist apomorphine, intended for rapid conversion from the OFF to the ON state; it has been studied to treat motor OFF episodes up to 5 times a day.

Primary Care Providers Have Mixed Views on Genetic Tests

May 14, 2018

They find tests for genetic risk potentially useful, but lack confidence in interpreting results

FDA Targets Clinics Offering Unapproved Stem Cell Therapies

May 11, 2018

The clinic claims its unapproved therapies can treat a number of serious diseases and conditions, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), chronic obstructive pulmonary disease (COPD), heart disease, and pulmonary fibrosis.

Acadia Addresses Concerns Over Nuplazid Safety in Parkinson's Disease Patients

By April 27, 2018

Concerns over Nuplazid were initially voiced in a CNN article in early April which reported that the drug had been associated with over 700 deaths since its launch in March 2017.

Exposure to Anti-TNF Therapy Linked to Reduced Parkinson's Disease Risk

By April 24, 2018

Previous research has suggested a genetic and functional link between IBD and PD, however evidence regarding this association has been limited.

Long-Term Benefits of Gocovri Observed in PD Patients With Dyskinesia

By April 19, 2018

By 2 years, 30% of patients had increased their levodopa dose by ~300mg, indicating that treatment with Gocovri may allow for further levodopa optimization despite the occurrence of dyskinesia.

FDA-Approved App Allows Clinicians to Objectively Measure Balance

By April 18, 2018

The application assesses 3 key balance metrics: (1) double stance, (2) right tandem stance, and (3) left tandem stance.

Untrimmed Toenails: A Marker of Functional Status in Older Patients?

By April 13, 2018

For older patients, toenail length can provide important insight into a patient's functional status.

NDA Submitted for Sublingual Film to Treat OFF Episodes in Parkinson's Disease

By March 30, 2018

The NDA submission included data from Phase 3, 12-week, randomized, double-blind, placebo-controlled, parallel-group study (CTH-300) that enrolled patients with levodopa-responsive Parkinson's disease complicated by OFF episodes.

FDA to Review Xeomin for the Management of Excessive Drooling

By March 14, 2018

The sBLA is based on a Phase 3, randomized, double-blind, placebo-controlled, multicenter 184 subject trial.

Can Tears Be Used to Diagnose Parkinson's Disease?

February 23, 2018

The researchers observed a significant decrease in total alpha-synuclein in tears from PD patients relative to healthy controls (423.12 ± 52.6 versus 703.61 ± 136.4 pg/mg tear protein). PD patients also had significantly increased oligomeric alpha-synuclein relative to controls (1.45 ± 0.31 versus 0.27 ± 0.07ng/ng tear protein).

FDA Accepts NDA for Orally Inhaled Levodopa Therapy Inbrija

By February 21, 2018

Inbrija (previously known as CVT-301) is a self-administered, orally inhaled levodopa; it is designed to deliver a precise dose of a dry powder formulation of L-dopa to the lung.

Osmolex ER OK'd for Parkinson's Disease, Drug-Induced Extrapyramidal Reactions

By February 20, 2018

The approval of Osmolex ER was based on bioavailability studies comparing Osmolex ER to immediate-release amantadine.

Apomorphine Film Effectively Converts OFF to ON State in PD Patients

By January 30, 2018

The difference in score change for movement disorder from baseline to 30 minutes post-dose between the apomorphine and placebo group was 7.6 (P=0.0002).

Gocovri Now Available to Treat Dyskinesia in Parkinson's Disease Patients

By January 09, 2018

Gocovri is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Caffeine Metabolism and Parkinson's Disease: What's the Link?

January 04, 2018

Significant decreases in serum levels of caffeine and nine of its metabolites seen in patients with early PD

Vercise Deep Brain Stimulation System Approved for Parkinson's Disease

By December 12, 2017

The FDA's approval was based on results from the 'Intrepid' study, the first multi-center, prospective, double-blind, randomized sham-controlled study of DBS for Parkinson's Disease in the U.S.

Anticholinergic Scoring Systems Appraised in Clinical Settings

November 28, 2017

The researchers found that the ACB showed the strongest and most consistent dose-response relationships with risks of all four adverse outcomes compared with ARS and DBI-Ach, especially among those aged 65 to 84 years.

Agranulocytosis Cases Prompt More Monitoring for Investigational Parkinson's Drug

By November 16, 2017

Dependent on further input from the Data Safety Monitoring Board (DSMB) and the Food and Drug Administration (FDA), the Company stated that they intend on moving forward with the study and expect to report results in the first quarter of 2018.

Sodium Oxybate Evaluated for Sleep-Wake Disturbances in PD Patients

November 08, 2017

Improvements in subjective sleep quality, objectively measured slow-wave sleep duration

Smoking May Affect Genetic Link to Parkinson's Disease

October 24, 2017

"Our study provides the first evidence that smoking modifies the previously reported inverse association of rs660895-G with PD, and suggests that smoking and HLA-DRB1 are involved in common pathways, possibly related to neuroinflammation," conclude the authors.

Unique Oscillatory Dynamics of Bicycling Examined in Parkinson's

September 25, 2017

"Abnormal ~18 Hz oscillations are implicated in the pathophysiology of freezing of gait, and suppressing them may form a key strategy in developing potential therapies," the authors write.

Gocovri Approved to Treat Dyskinesia in Patients with Parkinson's Disease

By August 28, 2017

The safety and efficacy of Gocovri was seen in two Phase 3 controlled trials in Parkinson's disease patients with dyskinesia.

Mislabeled Muscle Spasm, Parkinson's Drugs Prompt Recall

By July 28, 2017

Accidental dosing with Cyclobenzaprine HCl may potentially lead to life-threatening serotonin syndrome when the drug is taken in combination with selective serotonin reuptake inhibitors.

The Puzzles That May Improve Brain Performance

July 18, 2017

"We found direct relationships between the frequency of word puzzle use and the speed and accuracy of performance on nine cognitive tasks assessing a range of aspects of function including attention, reasoning, and memory," researcher Keith Wesnes, PhD.

ALS, Parkinson's Mortality Tied to Certain Occupations

July 14, 2017

Occupations associated with higher education and income show increased mortality risk

Early Biomarker May Help Differentiate Parkinsonism Disorders

July 12, 2017

Magnetic resonance imaging (T1-weighted and diffusion-weighted imaging) with a 3-T magnetic resonance imager revealed that the Parkinson's patients had significant alterations in optic radiation connectivity distribution.